Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

Recruiting now · Phase 1

Conditions studied: Diffuse Alveolar Hemorrhage, Antineutrophil Cytoplasmic Antibody Positive Vasculitis

In brief

The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with active severe GPA or MPA with diffuse alveolar hemorrhage (DAH) requiring mechanical ventilation for respiratory support.

Key facts

Study ID

NCT07556484

Run by

Mayo Clinic

People needed

6

Starts

2026-08-01

Expected to finish

2028-03-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fulfillment of the definitions of the Second Chapel Hill Consensus Conference for ANCA-associated vasculitis (either granulomatosis with polyangiitis (GPA) or microscopic polyangiitis MPA).
• Positivity for ANCA, directed against PR3 or MPO.
• Diffuse alveolar hemorrhage.
• Respiratory failure requiring mechanical ventilation.
• Severe newly diagnosed disease or severe relapsing disease. Severe new or relapsing disease is defined as at least one major BVAS/WG item or a score ≥ 3 and the investigator deems standard treatment for severe disease is necessary.
• Minimum BVAS-WG of 3.
• Requirement of standard-of-care remission induction therapy for active severe ANCA-associated vasculitis (GPA or MPA).

You may not qualify if…

• Diagnosis with eosinophilic granulomatosis with polyangiitis (EGPA, formally Churg-Strauss syndrome) as defined by the Chapel Hill consensus conference.
• Allergies: History of severe allergic reaction to avacopan
• History of documented anti-glomerular basement membrane disease (anti-GBM disease)
• Previous administration of avacopan within the last 5 days.
• Concomitant use of a strong CYP3A4 inhibitor.
• Aspartate aminotransferase [AST], alanine amino transferase [ALT], alkaline phosphatase, or total bilirubin elevation >2.5 times the upper limit of normal (unless attributed to vasculitis) on routine liver function testing obtained within 3 days prior to anticipated treatment with avacopan.
• Evidence of prior active or current Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency (HIV) infection.
• Active serious infection, including localized infection.
• Pregnancy and breastfeeding

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.